Global leading research pharma company Glenmark Pharmaceuticals mentioned in a company statement, “Results from the Phase 3 trial showed numerical improvements for the primary efficacy endpoint with 28.6 per cent faster viral clearance in the overall population as measured by the median time until cessation of oral shedding of virus in the Favipiravir treatment arm compared to those in the control arm.”
The Favipiravir treatment arm over the control arm revealed efficacy and benefit, a study highlighted.
On Thursday, the company announced top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients, conducted across seven clinical sites in India.
Along with its efficacy, the safety and supportive care of Favipiravir compared to standard supportive care alone (control arm), in mild to moderate patients, randomized within a 48-hour window in RT-PCR COVID-19 positive cases, was also evaluated. The open-label randomized, multicenter clinical trial was conducted in a total of 150 patients.
The Favipiravir arm treatment observed faster clinical cure and viral clearance among patients than the routine care group randomization.
At least 40 per cent faster achievement of ‘clinical cure’ defined as the physician’s assessment of normalization of clinical signs – temperature, oxygen saturation, respiratory rate and cough with Favipiravir treatment saw quicker outcomes, The reduction in median time to clinical cure in the Favipiravir treatment arm (three days), compared to the control arm (five days) was statistically significant.
Glenmark Pharmaceuticals rose as much as 4.06% on Thursday after the company announced top-line results from phase 3 clinical trial of Favipiravir in patients with COVID-19 symptoms. At 1:08 pm, shares of Glenmark Pharmaceuticals were trading at Rs 421.95 apiece on BSE, up 2% from its previous close, while the benchmark Sensex advanced 0.5% to 38,061.27 points.
Glenmark has received manufacturing and marketing approval from India’s drug regulator for FabiFlu, making it the first approved oral medication in India for the treatment of mild to moderate COVID-19 patients.

Read EquityPandit’s Nifty Outlook for the Week